Phase 2 Study Assessing Efficacy and Safety of Crizotinib in Patients Harboring an Alteration on ALK, MET or ROS1

NCT02034981 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

246

Enrollment

OTHER

Sponsor class

Conditions

Hematologic Cancers
Solid Tumors
Metastatic Cancer

Interventions

DRUG: Crizotinib

Sponsor

UNICANCER

Collaborators

[object Object]
[object Object]
[object Object]